Uveitis - Pipeline Review, H2 2011

Uveitis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Uveitis - Pipeline Review, H2 2011', provides an overview of the Uveitis therapeutic pipeline. This report provides information on the therapeutic development for Uveitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uveitis. 'Uveitis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Uveitis.
- A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Uveitis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Uveitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Uveitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Uveitis Overview
Therapeutics Development
An Overview of Pipeline Products for Uveitis
Uveitis Therapeutics under Development by Companies
Uveitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Uveitis Therapeutics - Products under Development by Companies
Uveitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Uveitis Therapeutics Development
Abbott Laboratories
Inovio Biomedical Corporation
Santen Pharmaceutical Co., Ltd.
Lux Biosciences, Inc.
Novartis AG
Isotechnika Pharma Inc.
Genmab A/S
Celgene Corporation
Enzo Biochem, Inc.
Cerimon Pharmaceuticals, Inc.
Aciont Inc.
Artielle ImmunoTherapeutics, Inc.
AnaptysBio, Inc.
SARcode Corporation
Xencor, Inc.
Alimera Sciences, Inc.
ESBATech AG
Icon Bioscience, Inc.
Uveitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CC-10004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEB071 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AIN457 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Uveitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Steroid for Severe Uveitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HuMax-TAC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Voclosporin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGX-1027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR1118 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Uveitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xpro1595 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESBA 105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iluvien - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EGP-437 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Optiquel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Luveniq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Luveniq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enbrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Raptiva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leflunomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Humira + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Daclizumab + Denileukin Diftitox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Gamma- 1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triamcinolone Acetonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Microplasmin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Beta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simulect - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketorolac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myfortic + Decortin H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Interferon-Alpha2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MS-553 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANB004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PA-2612 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uveitis Therapeutics – Drug Profile Updates
Uveitis Therapeutics - Discontinued Products
Uveitis - Featured News
Oct 18, 2011: Lux Biosciences Withdraws Marketing Authorization Application For Luveniq
Sep 12, 2011: pSivida Announces Opening Of Investigator-Sponsored Trial For Injectable, Sustained Release FAc Insert For Posterior Uveitis
Sep 08, 2011: Santen Announces EMA Orphan Drug Status For Sirolimus
Jun 24, 2011: Lux Biosciences To Appeal EMA Decision On Luveniq
Apr 14, 2011: CHMP Adopts Positive Opinion For Ozurdex In Non-Infectious Uveitis
Feb 24, 2011: Isotechnika Pharma's Partner, Lux Biosciences, Starts Enrollment In Phase III Uveitis Study
Nov 10, 2010: XOMA Announces Positive XOMA 052 Results In Treatment Of Behcet's Uveitis
Oct 04, 2010: Enzo Biochem Initiates Clinical Trial Of Optiquel For Treatment Of Uveitis At NIH
Sep 24, 2010: Allergan Receives FDA Approval For OZURDEX As Treatment For Non-Infectious Uveitis
Aug 04, 2010: Lux Biosciences Receives FDA's Complete Response Letter For Luveniq
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer